Sage cuts a third of its workforce after R&D setbacks
Sage said in an SEC filing that it expects a non-recurring charge tied to the workforce reduction of $26 million to $28 million that will mainly be booked in the fourth quarter of this year. It said it would give an indication of its cash runway "in the near future."
Sage Therapeutics’ stock falls 4.7% as biotech unveils plan to cut 33% of workforce
Sage Therapeutics Inc.’s stock slid 4.7% Thursday, after the biotech said it’s cutting about 33% of its workforce as part of an overhaul of its business and pipeline that’s expected to extend its cash runway.
Sage Therapeutics Cuts Workforce by 33% in Reorganization, Focuses on ZURZUVAE Launch and Pipeline
Several executives will depart as part of the changes, including Anne Marie Cook, Kimi Iguchi, Matt Lasmanis, Heinrich Schlieker, and Amy Schacterle. Chris Benecchi will be looking to take up the reins as Chief Operating Officer, overseeing several departments, while Greg Shiferman and Vanessa Procter will assume expanded leadership roles.
Sage Therapeutics Stock Is Dropping. A Workforce Reduction Is Hitting R&D Hard.
The biopharmaceutical company says the reorganization is meant to strengthen its balance sheet and position it for long-term growth.
Sage Therapeutics Cutting Workforce by 33% -- Update
Sage and Biogen last year won Food and Drug Administration approval of Zurzuvae as the first pill to treat postpartum depression, but the agency rejected the drug for major depressive disorder, a much larger opportunity, and Sage responded with a restructuring that included a 40% workforce reduction.
STAT10d
Biogen turns to telehealth company to boost its postpartum depression drug
Talkiatry partnership resembles efforts by pharma companies like Eli Lilly and Pfizer to team up with telehealth companies.
Sage Therapeutics Announces Strategic Reorganization to Prioritize ZURZUVAE® Commercialization and Focus its Development Portfolio
Sage Therapeutics, Inc. (Nasdaq: SAGE), today announced a strategic reorganization of its business operations to support the ongoing launch of ZURZUVAE in postpartum depression and focus pipeline ...
pharmaphorum9d
Biogen, Talkiatry team up on postpartum depression
The FDA approved Zurzuvae as the first oral therapy for post-partum depression (PPD) in August 2023, although, the agency ...
Business Wire22d
Sage Therapeutics Announces Discontinuation of the Collaboration with Biogen on the SAGE-324 Program
Sage and Biogen will continue to partner on ZURZUVAE® (zuranolone), the first and only FDA-approved oral treatment for women with postpartum depression (PPD) and will continue to work on their ...
Benzinga.com22d
Biogen Terminates Collaboration With Sage Therapeutics For Neurological Disorder Candidate
The companies will continue to collaborate on Zurzuvae, the FDA-approved treatment for postpartum depression. The companies recently announced negative results from the Phase 2 KINETIC 2 Study of ...